Literature DB >> 8849223

Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice.

L E Bermudez1, P Kolonoski, L S Young.   

Abstract

Roxithromycin alone reduced the level of bacteremia caused by Mycobacterium avium complex liver and splenic infection (in CFU per gram) of beige mice and mortality compared with untreated controls (P < 0.05). Roxithromycin plus ethambutol resulted in a significant reduction in the number of bacteria in splenic tissue compared with those in control splenic tissues of mice and mice treated with roxithromycin alone and ethambutol alone. Roxithromycin plus levofloxacin was not better than roxithromycin alone. Roxithromycin has in vivo activity against M. avium complex strains, and pilot studies with humans may be considered.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8849223      PMCID: PMC163255     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy.

Authors:  B Ji; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

2.  Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex.

Authors:  N Rastogi; V Labrousse
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  In vitro and in vivo activity of azithromycin (CP 62,993) against the Mycobacterium avium complex.

Authors:  C B Inderlied; P T Kolonoski; M Wu; L S Young
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

4.  Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex.

Authors:  M A Bertram; C B Inderlied; S Yadegar; P Kolanoski; J K Yamada; L S Young
Journal:  J Infect Dis       Date:  1986-07       Impact factor: 5.226

5.  Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS.

Authors:  L S Young; L Wiviott; M Wu; P Kolonoski; R Bolan; C B Inderlied
Journal:  Lancet       Date:  1991-11-02       Impact factor: 79.321

6.  In vitro and in vivo activities of clarithromycin against Mycobacterium avium.

Authors:  P B Fernandes; D J Hardy; D McDaniel; C W Hanson; R N Swanson
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

7.  Activity of clarithromycin against Mycobacterium avium complex infection in beige mice.

Authors:  S P Klemens; M S DeStefano; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

8.  Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice.

Authors:  L E Bermudez; C B Inderlied; P Kolonoski; M Wu; L Barbara-Burnham; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

9.  Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium.

Authors:  L B Heifets; P J Lindholm-Levy; R D Comstock
Journal:  Am Rev Respir Dis       Date:  1992-04

10.  In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin.

Authors:  K P Fu; S C Lafredo; B Foleno; D M Isaacson; J F Barrett; A J Tobia; M E Rosenthale
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

View more
  3 in total

1.  Drug evaluation of concurrent Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium complex infections in a rat model.

Authors:  M Brun-Pascaud; P Rajagopalan-Levasseur; F Chau; G Bertrand; L Garry; F Derouin; P M Girard
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

2.  Telithromycin is active against Mycobacterium avium in mice despite lacking significant activity in standard in vitro and macrophage assays and is associated with low frequency of resistance during treatment.

Authors:  L E Bermudez; C B Inderlied; P Kolonoski; M Wu; P Aralar; L S Young
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

3.  Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in mice.

Authors:  Luiz E Bermudez; Robert Reynolds; Peter Kolonoski; Pricilla Aralar; Clark B Inderlied; Lowell S Young
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.